

# CITATION REPORT

List of articles citing

Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases

DOI: 10.1136/ard.2007.072587

Annals of the Rheumatic Diseases, 2007, 66, 1547-8.

**Source:** <https://exaly.com/paper-pdf/41642806/citation-report.pdf>

**Version:** 2022-10-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
25	Manifestations cutanées des lupus érythémateux. <i>EMC - Dermatologie</i> , <b>2008</b> , 3, 1-16		0
24	Manifestaciones cutáneas de los lupus eritematosos. <i>EMC - Dermatología</i> , <b>2009</b> , 43, 1-16	0.1	
23	A new role for antimalarials in systemic lupus erythematosus treatment. <i>International Journal of Clinical Rheumatology</i> , <b>2010</b> , 5, 299-312	1	1
22	Antimalarials and SLE. <b>2011</b> , 1061-1081		0
21	Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 1968-70	1.1	22
20	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 522-33	7.8	140
19	Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 704-12	4.6	23
18	Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , <b>2012</b> , 37, 327-34	1.7	31
17	Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. <i>Anais Brasileiros De Dermatologia</i> , <b>2014</b> , 89, 118-25	1.5	7
16	Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 571-9	3	53
15	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2176-84	9.2	84
14	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134451	3.6	13
13	Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 634-9	3.4	65
12	Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, e79	3.4	4
11	Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. <i>Journal of the Neurological Sciences</i> , <b>2015</b> , 358, 131-7	1.4	31
10	The Cutaneous Spectrum of Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2017</b> , 53, 291-305	11.8	49
9	S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 389-404	4.5	73

8	Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 536-542	4.6	25
7	Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. <i>Postepy Dermatologii I Alergologii</i> , <b>2018</b> , 35, 192-198	1.4	3
6	Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102393	13.2	18
5	Hydroxychloroquine in dermatology: New perspectives on an old drug. <i>Australasian Journal of Dermatology</i> , <b>2020</b> , 61, e150-e157	1.2	11
4	Antimalarial Agents. <b>2021</b> , 234-244.e4		1
3	Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. <i>Journal of Drug Delivery Science and Technology</i> , <b>2021</b> , 63, 102512	4.2	0
2	Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.. <i>Journal of Dermatology</i> , <b>2022</b> ,	1.5	
1	Antimalarial agents. <b>2013</b> , 241-251.e3		